Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $40.00 Price Target at Needham & Company LLC

Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target lifted by stock analysts at Needham & Company LLC from $36.00 to $40.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 47.60% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a report on Wednesday, June 24th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.67.

Arcutis Biotherapeutics Stock Up 4.1%

ARQT stock opened at $27.10 on Thursday. The company’s 50 day moving average is $25.87 and its two-hundred day moving average is $24.68. Arcutis Biotherapeutics has a twelve month low of $13.69 and a twelve month high of $31.77. The company has a current ratio of 2.68, a quick ratio of 2.46 and a debt-to-equity ratio of 0.54. The stock has a market cap of $3.39 billion, a P/E ratio of -903.03 and a beta of 1.49.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. The firm had revenue of $129.86 million during the quarter, compared to analysts’ expectations of $118.85 million. Research analysts expect that Arcutis Biotherapeutics will post 0.16 earnings per share for the current fiscal year.

Insider Activity at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Todd Watanabe sold 4,375 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $114,275.00. Following the completion of the transaction, the insider owned 717,203 shares in the company, valued at approximately $18,733,342.36. The trade was a 0.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Masaru Matsuda sold 1,230 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $32,127.60. Following the completion of the sale, the insider directly owned 126,171 shares in the company, valued at $3,295,586.52. This trade represents a 0.97% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 16,894 shares of company stock valued at $422,044. 9.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. SBI Securities Co. Ltd. raised its stake in Arcutis Biotherapeutics by 325.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock valued at $32,000 after purchasing an additional 833 shares during the last quarter. Global Retirement Partners LLC purchased a new position in shares of Arcutis Biotherapeutics during the fourth quarter valued at approximately $35,000. EverSource Wealth Advisors LLC boosted its position in Arcutis Biotherapeutics by 124.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock worth $37,000 after acquiring an additional 698 shares during the last quarter. NewEdge Advisors LLC raised its holdings in Arcutis Biotherapeutics by 209.0% in the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock valued at $45,000 after acquiring an additional 1,045 shares during the last quarter. Finally, Truvestments Capital LLC lifted its stake in shares of Arcutis Biotherapeutics by 114.2% during the 4th quarter. Truvestments Capital LLC now owns 3,012 shares of the company’s stock worth $87,000 after purchasing an additional 1,606 shares during the period.

Key Stories Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Q2 results exceeded expectations: Arcutis reported earnings of $0.11 per share, above estimates of $0.06–$0.09 and substantially better than the $0.13-per-share loss recorded a year earlier. Revenue reached $129.9 million, beating the $118.9 million consensus estimate and increasing 59% year over year. Arcutis second-quarter 2026 results
• Positive Sentiment: Higher sales outlook: Management raised 2026 net product sales guidance to $525 million–$540 million, reflecting continued demand for ZORYVE. The company also reported positive operating cash flow for the quarter, supporting the improving commercial profile. Arcutis business update
• Positive Sentiment: Regulatory and pipeline catalysts expanded: The FDA approved ZORYVE cream 0.3% for plaque psoriasis in children as young as two. An application covering infants aged three to 24 months with atopic dermatitis was accepted for review, with a February 23, 2027 target action date. Enrollment also concluded in a Phase 2 vitiligo study, with results expected in the fourth quarter of 2026. ZORYVE regulatory and pipeline update
• Neutral Sentiment: Insider selling was limited: Three insiders sold a combined 6,560 shares worth approximately $171,000. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax obligations from vested equity awards, reducing their value as a bearish signal. ARQT insider transactions

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.